The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2020 | BTK inhibtors in CLL
Richard Furman, MD, of the Weill Cornell Medical College, New York, NY, updates us on the use of BTK inhibitors in the treatment of chronic lymphocytic leukemia (CLL) as well as the development of third-generation BTK inhibitors that are currently in Phase II studies. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
